Share

Ebola vaccine trial resumes

Geneva - The clinical trial of an Ebola vaccine developed by Merck and NewLink resumed on Monday at a lower dose after a pause to assess complaints of joint pains in some volunteers, the University of Geneva hospital said.

An Ebola outbreak, the worst on record of the highly infectious haemorrhagic fever, has killed over 7 900 people over the past year, with more than 20 000 cases recorded mostly in Guinea, Sierra Leone and Liberia, according to the World Health Organisation (WHO). The virus is still spreading in West Africa, especially in Sierra Leone.

Disappeared rapidly

The Geneva hospital announced on 11 December that its vaccine trial had been suspended as a precautionary measure after four patients complained of joint pains.  The hospital said 10 of 59 volunteers who received the vaccine had felt pains in their joints "similar to rheumatism" after some two weeks, but these symptoms had disappeared rapidly without any treatment.

Swissmedic, the Swiss regulatory agency, and ethics and safety committees have approved the resumption of the trial at a lower dose, the hospital said in a statement.

"The second part of this clinical trial will now test a dose of 300 000 vaccine particles, which should be better tolerated by volunteers and will hopefully trigger the production of enough antibodies," it said, noting that the initial phase had 10 million to 50 million vaccine particles.

Low dose of vaccine

"Fortunately", it said, the Merck-NewLink candidate vaccine "seems able to induce the production of antibodies at lower doses than those previously used" in the Geneva trial.

Vaccinations have now resumed for the last 56 volunteers, who will receive either a low dose of the vaccine or a placebo, by groups of 15 each week through January, it said.

Geneva researchers are constantly exchanging information with teams carrying out similar studies in Canada, Gabon, Germany and the United States, the hospital said. Final results are expected in March 2015.


We live in a world where facts and fiction get blurred
Who we choose to trust can have a profound impact on our lives. Join thousands of devoted South Africans who look to News24 to bring them news they can trust every day. As we celebrate 25 years, become a News24 subscriber as we strive to keep you informed, inspired and empowered.
Join News24 today
heading
description
username
Show Comments ()
Rand - Dollar
18.90
+0.2%
Rand - Pound
23.86
+0.2%
Rand - Euro
20.36
+0.3%
Rand - Aus dollar
12.31
+0.3%
Rand - Yen
0.12
+0.2%
Platinum
908.05
0.0%
Palladium
1,014.94
0.0%
Gold
2,232.75
-0.0%
Silver
24.95
-0.1%
Brent Crude
87.00
+1.8%
Top 40
68,346
0.0%
All Share
74,536
0.0%
Resource 10
57,251
0.0%
Industrial 25
103,936
0.0%
Financial 15
16,502
0.0%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE
Government tenders

Find public sector tender opportunities in South Africa here.

Government tenders
This portal provides access to information on all tenders made by all public sector organisations in all spheres of government.
Browse tenders